AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25731939 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants born SGA
Number of subjects: 0
Study 25731939 — intervention group
Group type: COMPARATOR
Intervention: Participants born AGA
Number of subjects: 0
Study 25154148 — intervention group
Group type: EXPERIMENTAL
Intervention: Operative treatment
Number of subjects: 30
Study 25154148 — intervention group
Group type: COMPARATOR
Intervention: Non-operative treatment
Number of subjects: 30
Study 21788663 — intervention group
Group type: EXPERIMENTAL
Intervention: Idebenone 900 mg/day
Number of subjects: 85
Study 21788663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study 18637091 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg once daily
Number of subjects: 991
Study 18637091 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 991
Study 17126775 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine scalp block (SB group)
Number of subjects: 16
Study 17126775 — intervention group
Group type: COMPARATOR
Intervention: Saline control (C group)
Number of subjects: 16
Study 14630260 — intervention group
Group type: COMPARATOR
Intervention: 70 Gy
Number of subjects: 1087
Study 14630260 — intervention group
Group type: EXPERIMENTAL
Intervention: 78 Gy
Number of subjects: 1087
Study 14630260 — intervention group
Group type: EXPERIMENTAL
Intervention: 64-66 Gy
Number of subjects: 1087
Study 14630260 — intervention group
Group type: EXPERIMENTAL
Intervention: 68-70 Gy
Number of subjects: 1087
Study 10690882 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg daily)
Number of subjects: 425
Study 10690882 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogen (CEE; 0.625 mg daily)
Number of subjects: 425
Study 10690882 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (10 mg daily) plus CEE (0.625 mg daily)
Number of subjects: 425
Study 10690882 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 425
Study 9350365 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane 7% with nitrous oxide 50% in oxygen for three minutes (Group A)
Number of subjects: 24
Study 9350365 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional slow induction with increasing sevoflurane concentration up to 5% with nitrous oxide 50% in oxygen (Group B)
Number of subjects: 24
Study 9350365 — intervention group
Group type: COMPARATOR
Intervention: Thiamylal 5 mg.kg-1 with inhalation of 100% oxygen (Group C)
Number of subjects: 24
Study 1443509 — intervention group
Group type: EXPERIMENTAL
Intervention: Racemic ketamine 2 mg/kg bw
Number of subjects: 30
Study 1443509 — intervention group
Group type: EXPERIMENTAL
Intervention: S-(+)-ketamine 1 mg/kg bw
Number of subjects: 30
Study 1443509 — intervention group
Group type: EXPERIMENTAL
Intervention: S-(+)-ketamine 1 mg/kg bw with midazolam 0.1 mg/kg i.v.
Number of subjects: 30
Study 2422103 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin plus aprotinin (10,000 KIU for every 10 U.I. insulin)
Number of subjects: 19
Study 2422103 — intervention group
Group type: COMPARATOR
Intervention: Insulin by itself
Number of subjects: 19
Study 31331348 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-physician clinicians (MLs) in intervention hospitals
Number of subjects: 16
Study 31331348 — intervention group
Group type: COMPARATOR
Intervention: Control group (hospitals without MLs)
Number of subjects: 16
Study 31331348 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-physician clinicians (MLs) and medically trained doctors (MDs) in intervention hospitals
Number of subjects: 16
Study 29846956 — intervention group
Group type: EXPERIMENTAL
Intervention: Supersized alcopops
Number of subjects: 309
Study 29846956 — intervention group
Group type: COMPARATOR
Intervention: Beer
Number of subjects: 309
Study 26707592 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostamatinib 200 mg BID
Number of subjects: 68
Study 26707592 — intervention group
Group type: EXPERIMENTAL
Intervention: Fostamatinib 100 mg BID
Number of subjects: 68
Study 24306002 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacille Calmette-Guerin (BCG)
Number of subjects: 82
Study 24306002 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacille Calmette-Guerin (BCG) + DMT
Number of subjects: 82
Study 24306002 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 22196968 — intervention group
Group type: EXPERIMENTAL
Intervention: 1-year treatment: induction: IFN alfa-2b, 10 MU (flat dose), SC, 5 days/week, 4 weeks, maintenance: IFN alfa-2b, 10 MU (flat dose), SC, 3 days/week for 12 months (n = 285)
Number of subjects: 855
Study 22196968 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 years of same treatment as Arm B (n = 285)
Number of subjects: 855
Study 22196968 — intervention group
Group type: COMPARATOR
Intervention: Observation only (n = 284)
Number of subjects: 855
Study 20658921 — intervention group
Group type: EXPERIMENTAL
Intervention: Acapella
Number of subjects: 30
Study 20658921 — intervention group
Group type: COMPARATOR
Intervention: Threshold inspiratory muscle trainer
Number of subjects: 30
Study 16359823 — intervention group
Group type: EXPERIMENTAL
Intervention: Psoriasis patients (PSO)
Number of subjects: 23
Study 16359823 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (n=25)
Number of subjects: 23
Study 15316947 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (neuroleptic known to prolong QTc)
Number of subjects: 0
Study 15316947 — intervention group
Group type: COMPARATOR
Intervention: Two-step off-drug QT correction analysis
Number of subjects: 0
Study 15316947 — intervention group
Group type: EXPERIMENTAL
Intervention: One-step off- and on-drug QT analysis
Number of subjects: 0
Study 11139800 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin 5000 units subcutaneously every 8 hours
Number of subjects: 0
Study 11139800 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40 mg subcutaneously daily
Number of subjects: 0
Study 9265931 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 5 micrograms.kg‐1 with bupivacaine 0.175%
Number of subjects: 40
Study 9265931 — intervention group
Group type: COMPARATOR
Intervention: Control group with bupivacaine 0.175%
Number of subjects: 40
Study 8396082 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 1129
Study 8396082 — intervention group
Group type: COMPARATOR
Intervention: Comparator agents (co-amoxiclav, amoxycillin, penicillin V, erythromycin, dicloxacillin, flucloxacillin)
Number of subjects: 1129
Study 8396082 — intervention group
Group type: COMPARATOR
Intervention: Comparator agents
Number of subjects: 1129
Study 3089691 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimoprostil 1.5 mg
Number of subjects: 11
Study 3089691 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimoprostil 3.0 mg
Number of subjects: 11
Study 3089691 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 31045455 — intervention group
Group type: EXPERIMENTAL
Intervention: AVF ligation
Number of subjects: 64
Study 31045455 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 64
Study 29924907 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of meglumine antimoniate (20 mg SbV/kg/day for 20 days) and oral tamoxifen (40 mg/day for 20 days)
Number of subjects: 38
Study 29924907 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of meglumine antimoniate (20 mg SbV/kg/day for 20 days) and topical tamoxifen (0.1% tamoxifen citrate for 20 days)
Number of subjects: 38
Study 29924907 — intervention group
Group type: COMPARATOR
Intervention: Standard meglumine antimoniate (20 mg/kg/day for 20 days)
Number of subjects: 38
Study 27084921 — intervention group
Group type: EXPERIMENTAL
Intervention: Isavuconazole (20, 40, or 60 mg/kg every 24 h after a 90 mg/kg loading dose for 12 days)
Number of subjects: 0
Study 27084921 — intervention group
Group type: EXPERIMENTAL
Intervention: Isavuconazole (clinical dosing regimen)
Number of subjects: 0
Study 27084921 — intervention group
Group type: COMPARATOR
Intervention: Isavuconazole
Number of subjects: 0
Study 25420830 — intervention group
Group type: EXPERIMENTAL
Intervention: Liberal fluid strategy (Group A)
Number of subjects: 89
Study 25420830 — intervention group
Group type: COMPARATOR
Intervention: Restrictive fluid therapy (Group B)
Number of subjects: 89
Study 23186301 — intervention group
Group type: EXPERIMENTAL
Intervention: AGATE intervention (cell-phone-based intervention with SMS text message reminders)
Number of subjects: 105
Study 23186301 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no specific intervention details provided)
Number of subjects: 105
Study 20359937 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain biology education and group exercise classes (EDEX)
Number of subjects: 38
Study 20359937 — intervention group
Group type: COMPARATOR
Intervention: Pain biology education alone (ED)
Number of subjects: 38
Study 18541792 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of lesions on baseline non-contrast-enhanced MRI
Number of subjects: 389
Study 18541792 — intervention group
Group type: COMPARATOR
Intervention: No lesions on baseline brain MRI
Number of subjects: 389
Study 18541792 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 or more lesions on baseline brain MRI
Number of subjects: 389
Study 18541792 — intervention group
Group type: COMPARATOR
Intervention: Baseline factors (male sex, optic disc swelling, atypical features) in patients without lesions
Number of subjects: 389
Study 17855096 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Strengthening (RS)
Number of subjects: 20
Study 17855096 — intervention group
Group type: COMPARATOR
Intervention: Active Exercise (AE)
Number of subjects: 20
Study 17855096 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RS and AE
Number of subjects: 20
Study 12914803 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual cognitive therapy
Number of subjects: 71
Study 12914803 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive therapy
Number of subjects: 71
Study 12914803 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 71
Study 10966892 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A-fortified pandesal (60g containing approximately 133 microg retinol equivalents), consumed 5 days/week for 30 weeks
Number of subjects: 835
Study 10966892 — intervention group
Group type: COMPARATOR
Intervention: Nonfortified pandesal, consumed 5 days/week for 30 weeks
Number of subjects: 835
Study 10966892 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A-fortified pandesal
Number of subjects: 835
Study 9574332 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic pen for subcutaneous injections of low molecular heparin
Number of subjects: 51
Study 8365195 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg beta-carotene and 25,000 IU vitamin A as retinyl palmitate (intervention)
Number of subjects: 18000
Study 8365195 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 18000
Study 3944976 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide
Number of subjects: 219
Study 3944976 — intervention group
Group type: COMPARATOR
Intervention: Bismuth subsalicylate
Number of subjects: 219
Study 29966112 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (TA)
Number of subjects: 140
Study 29966112 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 140
Study 26096349 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic and complex skills (Group B)
Number of subjects: 55
Study 26096349 — intervention group
Group type: COMPARATOR
Intervention: Basic skills (Group A)
Number of subjects: 55
Study 24973340 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction mammaplasty
Number of subjects: 60
Study 24973340 — intervention group
Group type: COMPARATOR
Intervention: Follow-up for 6 months
Number of subjects: 60
Study 23070968 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinoseptoplasty with inferior turbinate reduction through submucosal diathermy
Number of subjects: 50
Study 23070968 — intervention group
Group type: COMPARATOR
Intervention: Rhinoseptoplasty without inferior turbinate reduction
Number of subjects: 50
Study 23070968 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhinoseptoplasty with inferior turbinate reduction
Number of subjects: 50
Study 20958851 — intervention group
Group type: EXPERIMENTAL
Intervention: Women's Recovery Group (WRG)
Number of subjects: 36
Study 20958851 — intervention group
Group type: COMPARATOR
Intervention: Group Drug Counseling (GDC)
Number of subjects: 36
Study 20958851 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 36
Study 18840077 — intervention group
Group type: EXPERIMENTAL
Intervention: 750 mg single dose of orally administered fluconazole
Number of subjects: 220
Study 18840077 — intervention group
Group type: COMPARATOR
Intervention: 150 mg of orally administered fluconazole once per day for 2 weeks
Number of subjects: 220
Study 16650048 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotics (Lactobacillus rhamnosus and Bifidobacteria lactis)
Number of subjects: 59
Study 16650048 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 12828815 — intervention group
Group type: EXPERIMENTAL
Intervention: High causal uncertainty
Number of subjects: 72
Study 12828815 — intervention group
Group type: COMPARATOR
Intervention: Low causal uncertainty
Number of subjects: 72
Study 11379466 — intervention group
Group type: EXPERIMENTAL
Intervention: Griseofulvin 500 mg daily for 10 days
Number of subjects: 225
Study 11379466 — intervention group
Group type: COMPARATOR
Intervention: Placebo and personal hygiene (restricted bathing)
Number of subjects: 225
Study 8784124 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 24
Study 8784124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 1729427 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous cocaine administration
Number of subjects: 0
Study 1729427 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 6390194 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxandrolone
Number of subjects: 263
Study 6390194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 263
Study 6390194 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisolone
Number of subjects: 263
Study 29514317 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch (Nicoderm 14 mg)
Number of subjects: 31
Study 29514317 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine spray (Nicotrol, 2 × 1 mg/trial)
Number of subjects: 31
Study 29514317 — intervention group
Group type: COMPARATOR
Intervention: Placebo patch plus placebo spray
Number of subjects: 31
Study 28028730 — intervention group
Group type: EXPERIMENTAL
Intervention: Onartuzumab (MetMAb) + erlotinib
Number of subjects: 636
Study 28028730 — intervention group
Group type: COMPARATOR
Intervention: Erlotinib
Number of subjects: 636
Study 28028730 — intervention group
Group type: EXPERIMENTAL
Intervention: Onartuzumab exposure
Number of subjects: 636
Study 25790943 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 mg slow‐release isosorbide‐5-mononitrate (ISMN)
Number of subjects: 20
Study 25790943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 23194157 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin-exposed pregnancies
Number of subjects: 249
Study 23194157 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-exposed pregnancies)
Number of subjects: 249
Study 22355644 — intervention group
Group type: EXPERIMENTAL
Intervention: D-cycloserine (DCS)
Number of subjects: 0
Study 22355644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19325186 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivational synchronous music
Number of subjects: 30
Study 19325186 — intervention group
Group type: EXPERIMENTAL
Intervention: Oudeterous synchronous music
Number of subjects: 30
Study 19325186 — intervention group
Group type: COMPARATOR
Intervention: No-music control
Number of subjects: 30
Study 16462503 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-session structured multidisciplinary intervention
Number of subjects: 115
Study 16462503 — intervention group
Group type: COMPARATOR
Intervention: Standard-care arm
Number of subjects: 115
Study 16279258 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung-volume-reduction surgery (LVRS) plus medical treatment
Number of subjects: 0
Study 16279258 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment alone
Number of subjects: 0
Study 11744593 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightwand intubation (LN group)
Number of subjects: 88
Study 11744593 — intervention group
Group type: COMPARATOR
Intervention: Fibreoptic intubation (FN group)
Number of subjects: 88
Study 11744593 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightwand intubation (LH group)
Number of subjects: 88
Study 11744593 — intervention group
Group type: COMPARATOR
Intervention: Fibreoptic intubation (FH group)
Number of subjects: 88
Study 11744593 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques (lightwand and fibreoptic)
Number of subjects: 88
Study 9329348 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 mg hydrocortisone
Number of subjects: 15
Study 9329348 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 8440853 — intervention group
Group type: EXPERIMENTAL
Intervention: Various interventions from the FICSIT trials; specific interventions not detailed in the abstract.
Number of subjects: 0
Study 8440853 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified; details on control interventions not available.
Number of subjects: 0
Study 3525386 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral acyclovir plus 5% acyclovir cream
Number of subjects: 50
Study 3525386 — intervention group
Group type: COMPARATOR
Intervention: Oral acyclovir plus matching placebo cream
Number of subjects: 50
Study 31614330 — intervention group
Group type: EXPERIMENTAL
Intervention: Polarized training (POL)
Number of subjects: 20
Study 31614330 — intervention group
Group type: COMPARATOR
Intervention: Threshold training (THR)
Number of subjects: 20
Study 28566441 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly Jintrolong (0.2 mg/kg/week)
Number of subjects: 451
Study 28566441 — intervention group
Group type: COMPARATOR
Intervention: Daily rhGH (0.25 mg/kg/week)
Number of subjects: 451
Study 25986472 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth
Number of subjects: 3230
Study 25986472 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (RCT control group)
Number of subjects: 3230
Study 25986472 — intervention group
Group type: COMPARATOR
Intervention: Matched Nonparticipants (Usual Care)
Number of subjects: 3230
Study 23474384 — intervention group
Group type: EXPERIMENTAL
Intervention: UAE
Number of subjects: 177
Study 23474384 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysterectomy
Number of subjects: 177
Study 23474384 — intervention group
Group type: COMPARATOR
Intervention: Preference group (varied treatments)
Number of subjects: 177
Study 21937848 — intervention group
Group type: EXPERIMENTAL
Intervention: Astaxanthin supplementation (3 mg/day) for 4 or 12 weeks
Number of subjects: 0
Study 21937848 — intervention group
Group type: COMPARATOR
Intervention: Astaxanthin supplementation (1 mg/day)
Number of subjects: 0
Study 21937848 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19430742 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of two antihistamines (levocetirizine 10 mg/fexofenadine 360 mg)
Number of subjects: 67
Study 19430742 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of three antihistamines (levocetirizine 10 mg/fexofenadine 360 mg/azelastine 4 mg)
Number of subjects: 67
Study 19430742 — intervention group
Group type: EXPERIMENTAL
Intervention: High dosage desloratadine (20 mg)
Number of subjects: 67
Study 16377455 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated treatment
Number of subjects: 216
Study 16377455 — intervention group
Group type: COMPARATOR
Intervention: Parallel treatment
Number of subjects: 216
Study 15162242 — intervention group
Group type: COMPARATOR
Intervention: Long distance competitive cyclists
Number of subjects: 20
Study 12027916 — intervention group
Group type: EXPERIMENTAL
Intervention: 100% seizure reduction
Number of subjects: 134
Study 12027916 — intervention group
Group type: EXPERIMENTAL
Intervention: 75-99% seizure reduction
Number of subjects: 134
Study 12027916 — intervention group
Group type: EXPERIMENTAL
Intervention: 50-74% seizure reduction
Number of subjects: 134
Study 12027916 — intervention group
Group type: EXPERIMENTAL
Intervention: 0-50% increase or decrease in seizure frequency
Number of subjects: 134
Study 9564642 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH‐a (buserelin acetate, 600 μg/d for six weeks) plus hMG (conventional doses for 14 cycles)
Number of subjects: 20
Study 9564642 — intervention group
Group type: COMPARATOR
Intervention: Low-dose hMG (for 17 cycles)
Number of subjects: 20
Study 7647025 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg oral nicorandil
Number of subjects: 16
Study 7647025 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg oral nicorandil
Number of subjects: 16
Study 7647025 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 16
Study 2768721 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic pulse
Number of subjects: 22
Study 2768721 — intervention group
Group type: COMPARATOR
Intervention: Monophasic pulse
Number of subjects: 22
Study 2768721 — intervention group
Group type: COMPARATOR
Intervention: Both waveforms
Number of subjects: 22
Study 782146 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dosage heparin
Number of subjects: 110
Study 782146 — intervention group
Group type: COMPARATOR
Intervention: Control group (no heparin)
Number of subjects: 110
Study 31623498 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (20 mg/d) following ROCKET AF criteria
Number of subjects: 3162
Study 31623498 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (15 mg/d) following J-ROCKET AF criteria
Number of subjects: 3162
Study 31623498 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (15 mg/d) following ROCKET AF criteria
Number of subjects: 3162
Study 31623498 — intervention group
Group type: EXPERIMENTAL
Intervention: Rivaroxaban (10 mg/d) following J-ROCKET AF criteria
Number of subjects: 3162